Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - AbbVie

X
Drug Profile

Ciclosporin ophthalmic - AbbVie

Alternative Names: Cyclosporin - AbbVie; Cyclosporin ophthalmic emulsion; Cyclosporine - AbbVie; RESTASIS; Restasis; RESTASIS MULTIDOSE; Restasis X; Restaysis

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer AbbVie; Allergan
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratoplasty rejection; Corneal disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 20 Jul 2018 The US Court of Appeals for the Federal Circuit affirms the decision of the US Patent Trial and Appeal Board filed against Allergan by Mylan for patent disputes in USA
  • 07 Jun 2018 Launched for Dry eyes in North America (Ophthalmic) prior to June 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top